fagron semaglutide FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Oral Semaglutide Demonstrates Greater Weight

With our professional team on your side, our specialists look at what makes you unique, from your genetic predispositions to your family history

Nausea, vomiting, diarrhea, constipation, and stomach discomfort are common across the class, particularly early in treatment

Non-classic thyroid hormone signalling involved in hepatic lipid metabolism

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial

In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight